Tafenoquine

Edina Avdic, Pharm.D.
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS
Tafenoquine is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Two different brand names were FDA approved in 2018
    • Krintafel™- radical cure (prevention of relapse) of Plasmodium vivax malaria in patients ≥16 years old who are receiving appropriate antimalarial therapy for acute P. vivax infection.
      • Please note that tafenoquine is NOT indicated for the treatment of acute P. vivax malaria.
    • Arakoda™-prophylaxis of malaria in patients ≥18 years of age

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Two different brand names were FDA approved in 2018
    • Krintafel™- radical cure (prevention of relapse) of Plasmodium vivax malaria in patients ≥16 years old who are receiving appropriate antimalarial therapy for acute P. vivax infection.
      • Please note that tafenoquine is NOT indicated for the treatment of acute P. vivax malaria.
    • Arakoda™-prophylaxis of malaria in patients ≥18 years of age

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: July 3, 2020